Synthesis and biological evaluation of a new series of hexahydro-2 H-pyrano[3,2-c ]quinolines as novel selective σ1 receptor ligands

Journal of Medicinal Chemistry

Volumn 56, Issue 9, 2013, Pages 3656-3665

  Díaz, José Luis ^a   Christmann, Ute ^a   Fernández, Ariadna ^a   Luengo, Mónica ^a   Bordas, Magda ^a   Enrech, Raquel ^a   Carro, Mónica ^a   Pascual, Rosalia ^a   Burgueño, Javier ^a   Merlos, Manuel ^a   Benet Buchholz, Jordi ^b   Cerón Bertran, Jordi ^b   Ramírez, Jesús ^b   Reinoso, Raquel F ^a   Fernández De Henestrosa, Antonio R ^a   Vela, José Miguel ^a   Almansa, Carmen ^a  

^a Preclinical Development   (Spain)

^b INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA ICIQ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 BENZYLPIPERIDIN 4 YL) 9 (ISOPENTYLOXY) 3,4,4A,5,6,10B HEXAHYDRO 2H PYRANO[3,2 C]QUINOLINE; 5 (1 ETHYLPIPERIDIN 4 YL) 9 (ISOPENTYLOXY) 3,4,4A,5,6,10B HEXAHYDRO 2H PYRANO[3,2 C]QUINOLINE; 9 (ISOPENTYLOXY) 5 (PIPERIDIN 4 YL) 3,4,4A,5,6,10B HEXAHYDRO 2H PYRANO[3,2 C]QUINOLINE; 9 (ISOPENTYLOXY) 5 (TETRAHYDRO 2H PYRAN 4 YL) 3,4,4A,5,6,10B HEXAHYDRO 2H PYRANO[3,2 C]QUINOLINE; CAPSAICIN; FORMALDEHYDE; HEXAHYDRO 2H PYRANO[3,2 C]QUINOLINE DERIVATIVE; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIASTEREOISOMER; DRUG ACTIVITY; DRUG ADSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HIGH THROUGHPUT SCREENING; MALE; MOUSE; NEUROGENIC PAIN; NONHUMAN; PAIN; PHARMACOPHORE; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG EVALUATION, PRECLINICAL; FEMALE; GUINEA PIGS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MALE; MICE; MODELS, MOLECULAR; PHYSICOCHEMICAL PROCESSES; PROTEIN CONFORMATION; QUINOLINES; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877686385     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400181k     Document Type: Article

References (55)

1. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites Trends Pharmacol. Sci. 1992, 13, 85-86
2. Bowen, W. D. Sigma receptors: advances and new clinical potentials Helv. Pharm. Acta 2000, 74, 211-218
3. 1-binding site Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8072-8077
4. Kekuda, R.; Prasad, P. D.; Fei, Y. J.; Leibach, F. H.; Ganapathy, V. Cloning and functional expression of the human type 1 sigma Receptor (hSigmaR1) Biochem. Biophys. Res. Commun. 1996, 229, 553-558
5. Su, T. P.; Hayashi, T.; Maurice, T.; Buch, S.; Ruoho, A. E. The sigma-1 receptor chaperone as an inter-organelle signalling modulator Trends Pharmacol. Sci. 2010, 31, 557-566
6. Monnet, F. P.; Debonnel, G.; Junien, J. L.; De Montigny, C. N-methyl-d-aspartate-induced neuronal activation is selectively modulated by sigma receptors Eur. J. Pharmacol. 1990, 179, 441-445
7. Cheng, Z. X.; Lan, D. M.; Wu, P. Y.; Zhu, Y. H.; Dong, Y.; Ma, L.; Zheng, P. Neurosteroid dehydroepiandrosterone sulphate inhibits persistent sodium currents in rat medial prefrontal cortex via activation of sigma-1 receptors Exp. Neurol. 2010, 210, 128-136
8. Chien, C. C.; Pasternak, G. W. Selective antagonism of opioid analgesia by a sigma system J. Pharmacol. Exp. Ther. 1994, 271, 1583-1590
9. Kim, F. J.; Kovalyshyn, I.; Burgman, M.; Neilan, C.; Chien, C. C.; Pasternak, G. W. Sigma-1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding Mol. Pharmacol. 2010, 77, 695-703
10. Zamanillo, D.; Portillo-Salido, E.; Vela, J. M.; Romero, L. Sigma-1 receptor chaperone: pharmacology and therapeutic perspectives. In Therapeutic Targets: Modulation, Inhibition, and Activation; Botana, L. M.; Loza, M., Eds.; John Wiley & Sons: Hoboken, NJ, 2012; Chapter 6, pp 225-278.
11. Maurice, T.; Su, T. P. The pharmacology of sigma-1 receptors Pharmacol. Ther. 2009, 124, 195-206
12. Cendán, C. M.; Pujalte, J. M.; Portillo-Salido, E.; Montoliu, L.; Baeyens, J. M. Formalin-induced pain is reduced in sigma(1) receptor knockout mice Eur. J. Pharmacol. 2005, 511, 73-74
13. Entrena, J. M.; Cobos, E. J.; Nieto, F. R.; Cendán, C. M.; Gris, G.; Del Pozo, E.; Zamanillo, D.; Baeyens, J. M. Sigma-1 receptors are essential for capsaicin-induced mechanical hypersensitivity: studies with selective sigma-1 ligands and sigma-1 knockout mice Pain 2009, 143, 252-261
14. De la Puente, B.; Nadal, X.; Portillo-Salido, E.; Sánchez-Arroyos, R.; Ovalle, S.; Palacios, G.; Muro, A.; Romero, L.; Entrena, J. M.; Baeyens, J. M; López-García, J. A.; Maldonado, R.; Zamanillo, D.; Vela, J. M. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury Pain 2009, 145, 294-303
15. Drews, E.; Zimmer, A. Central sensitization needs sigma receptors Pain 2009, 145, 269-270
16. Díaz, J. L.; Zamanillo, D.; Corbera, J.; Baeyens, J. M.; Maldonado, R.; Pericàs, M. A.; Vela, J. M.; Torrens, A. Selective sigma-1 receptor antagonists: emerging target for the treatment of neuropathic pain Cent. Nerv. Syst. Agents Med. Chem. 2009, 9, 172-183
17. 1 receptor antagonists: identification of 4-{2-[5-methyl-1- (naphthalen-2-yl)-1 H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862) J. Med. Chem. 2012, 55, 8211-8224
18. 1) receptor binding: application of the " deconstruction-reconstruction-elaboration " approach Mini-Rev. Med. Chem. 2005, 5, 927-940
19. Marrazzo, A.; Cobos, E. J.; Parenti, C.; Arico, G.; Marrazzo, G.; Ronsisvalle, S.; Pasquinucci, L.; Prezzavento, O.; Colabufo, N. A.; Contino, M. A.; Gonzalez, L. G.; Scoto, M. G.; Ronsisvalle, G. Novel potent and selective σ ligands: evaluations of their agonist and antagonist properties J. Med. Chem. 2011, 54, 3669-3673
20. Xu, J.; Zeng, C.; Chu, W.; Pan, F.; Rothfuss, J. M.; Zhang, F.; Tu, Z.; Zhou, D.; Zeng, D.; Vangveravong, S.; Johnston, F.; Spitzer, D.; Chang, K. C.; Hotchkiss, R. S.; Hawkins, W. G.; Wheeler, K. T.; Mach, R. H. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site Nat. Commun. 2011, 2, 380
21. Ahmed, I. S.; Chamberlain, C.; Craven, R. J. S2R (Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling Expert Opin. Drug Metab. Toxicol. 2012, 8, 361-370
22. Crawford, K. W.; Bowen, W. D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines Cancer Res. 2002, 1, 313-322
23. Povarov, S. L. α,β-unsaturated ethers and their analogues in reactions of diene synthesis Russ. Chem. Rev. 1967, 36, 656-670
24. Koutznetsov, V. V. Recent synthetic developments in a powerful imino Diels-Alder reaction (Povarov reaction): application to the synthesis of N-polyhtereocycles and related alkaloids Tetrahedron 2009, 65, 2721-2750
25. Bello, D.; Ramon, R.; Lavilla, R. Mechanistic variations of the Povarov multicomponent reaction and related processes Curr. Org. Chem. 2010, 14, 332-356
26. Kamble, V. T.; Ekhe, V. R.; Joshi, N. S.; Biradar, A. V. Magnesium perchlorate: an efficient catalyst for the one-pot synthesis of pyrano-and furanoquinolines Synlett 2007, 9, 1379-1382
27. Xia, M.; Lu, Y. D. Molecular iodine catalyzed imino-Diels-Alder reaction: efficient one-pot synthesis of pyrano[3,2-c ]quinolines Synlett 2005, 15, 2357-2361
28. More, S. V.; Sastry, M. N. V.; Yao, C.-F. TMSCl-catalyzed aza-Diels-Alder reaction: a simple and efficient synthesis for furano-and pyranoquinolines Synlett 2006, 9, 1399-1403
29. 3H](+)pentazocine to recognition sites in guinea pig brain Eur. J. Pharmacol. 1992, 227, 371-378
30. Ronsisvalle, G.; Marrazzo, A.; Prezzavento, O.; Cagnotto, A.; Mennini, T.; Parenti, C.; Scoto, G. M. Opioid and sigma receptor studies. New developments in the design of selective sigma ligands Pure Appl. Chem. 2001, 73, 1499-1509
31. 1 receptor ligands with exocyclic amino moiety (increased distance 1) Bioorg. Med. Chem. 2011, 19, 3141-3151
32. 1 receptor binding J. Med. Chem. 1994, 37, 1214-1219
33. 1 receptors Curr. Pharm. Des. 2012, 18, 930-937
34. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 881-890
35. 1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening J. Med. Chem. 2005, 48, 4754-4764
36. Selectivity panel identical to that used for characterization of compound 1 as indicated in the following paper: Romero, L.; Zamanillo, D.; Nadal, X.; Sánchez-Arroyos, R.; Rivera-Arconada, I.; Dordal, A.; Montero, A.; Muro, A.; Bura, A.; Segalés, C.; Laloya, M.; Hernández, E.; Portillo-Salido, E.; Escriche, M.; Codony, X.; Encina, G.; Burgueño, J.; Merlos, M.; Baeyens, J. M.; Giraldo, J.; López-García, J. A.; Maldonado, R.; Plata-Salamán, C. R.; Vela, J. M. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization Br. J. Pharmacol. 2012, 166, 2289-2306
37. Kim, H. W.; Kwon, Y. B.; Roh, D. H.; Yoon, S. Y.; Han, H. J.; Kim, K. W.; Beitz, A. J.; Lee, J. H. Intrathecal treatment with sigma1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice Br. J. Pharmacol. 2006, 148, 490-498
38. Stresser, D. M. High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates. Methodology for 25 enzyme/substrate pairs. In Optimization in Drug Discovery: In Vitro Methods; Yan, Z.; Caldwell, G. W., Eds.; Humana Press: Totowa, NJ, 2004; pp 215-230.
39. Yan, Z.; Caldwell, G. W. Evaluation of cytochrome P450 inhibition in human liver microsomes. In Optimization in Drug Discovery: In Vitro Methods; Yan, Z.; Caldwell, G. W., Eds.; Humana Press: Totowa, NJ, 2004; pp 231-244.
40. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing and Labeling; Center for Drug Evaluation and Research (CDER), Food and Drug Administration: Silver Spring, MD, September 2006, and February 2012.
41. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 1997, 283, 46-58
42. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Am. Soc. Pharmacol. Exp. Ther. 1999, 27, 1350-1359
43. Putman, K. P. Evaluation of eight in vitro assays for assessing the cytotoxicity of cigarette smoke condensate Toxicol. Vitro 2000, 16, 599-607
44. Maron, D. M.; Ames, B. N. Revised methods for the Salmonella mutagenicity test Mutat. Res. 1983, 113, 173-215
45. Reifferscheid, G.; Heil, J. Validation of the SOS/umu test using test results of 486 chemicals and comparison with the Ames test and carcinogenicity data Mutat. Res. 1996, 369, 129-145
46. o J. Pharmacol. Toxicol. Methods 2004, 50, 187-199
47. Sugano, K.; Okazaki, A.; Sugimoto, S.; Tavornvipas, S.; Omura, A.; Mano, T. Solubility and dissolution profile assessment in drug discovery Drug Metab. Pharmacokinet. 2007, 22 (4) 225-254
48. Box, K. J.; Comer, E. A. Using measured pKa, logP and solubility to investigate supersaturation and predict BCS class Curr. Drug Metab. 2008, 9, 869-878
49. Data collection with APEX II versions v2009.1-02, Bruker AXS Inc., Madison, WI, 2007.
50. Data reduction with Bruker SAINT V7.60A, Bruker AXS Inc., Madison, WI, 2007.
51. SADABS, V2008/1, Bruker AXS Inc., Madison, WI, 2001.
52. Blessing, R. H. An empirical correction for absorption anisotropy Acta Crystallogr. 1995, A51, 33-38
53. Sheldrick, G. M. A short history of SHELX Acta Crystallogr. 2008, A64, 112-122
54. Flack, H. D. On enantiomorph-polarity estimation Acta Crystallogr. 1983, A39, 876-881
55. Discovery Studio Modeling Environment, release 3.5; Accelrys Software Inc.: San Diego, 2012.